First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma MGMT Methylated Contact Us Summary This trial aims to evaluate the addition of an autologous tumor lysate-pulsed Dendritic Cell vaccine (DCVax®-L) to standard therapy for patients diagnosed with glioblastoma. The findings suggest the addition […]

Adjuvant immunotherapy with autologous dendritic cells (LANEX-DC) in rectal cancer

Adjuvant immunotherapy with autologous dendritic cells (LANEX-DC) in rectal cancer Dendritic Cells attacking tumour cells Contact Us Summary Despite adjuvant chemotherapy and radiotherapy, recurrence or metastasis rates after curative resection of rectal cancer are up to 60% depending on the stage of the tumour. In this retrospective cohort analysis, the effect of additive immunotherapy with […]

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination Overall survival rate Contact Us Summary The objective is analyze the safety and survival of melanoma patients with regional metastatic disease who underwent a RLND and received adjuvant DC vaccination. Introduction The incidence of cutaneous melanoma continues to rise worldwide. Adequate surgical […]

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial SLN cumulative response Contact Us Summary This trial confirms the safety of neoadjuvant DC1 vaccination for patients with early invasive breast cancer (IBC). The immune response in the sentinel lymph nodes, may serve as […]

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer

Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer Contact Us Summary In this study it was hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy […]

Dendritic-Cells: the latest weapon in the fight against cancer

Dendritic-Cells: the latest weapon in the fight against cancer Clinical study on Malignant Astrocytoma Contact Us Summary This study is based on Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and […]